BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
Business Insider8h
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...
ETF Daily News13h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Invesco Health Care Fund Q3 2024 Commentary
Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is ...
Zacks.com on MSN23h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...